United Kingdom-based GW Pharmaceuticals Plc will be acquired by Jazz Pharmaceuticals Plc in a $7.2 billion cash-and-stock deal, MarketWatch reports. The deal, announced this week, is expected to close sometime in the second quarter of 2021 in hopes of boosting first-year profits after the close and in order to drive additional revenue growth.
GW Pharmaceuticals’ pre-market stock prices soared 46% following the announcement.
GW Pharma is the manufacturer of Epidiolex, an oral solution which in 2018 became the first cannabis-based medication to receive FDA approval for patient use. Jazz Pharma is an Ireland-based biopharmaceutical company founded in 2003.
Epidiolex utilizes CBD to treat seizure symptoms. The medication was originally approved to treat Dravet syndrome, a rare and drug-resistant form of epilepsy, but in August 2020, the FDA also approved the drug as a treatment for seizures resulting from tuberous sclerosis complex.
Nawan Butt, the Portfolio Manager of The MEdical Cannabis and Wellness UCITS ETF (Europe’s first cannabis-focused ETF), said the deal could signal a significant shift in the international cannabis market.
“When [GW] started most global pharma companies were hesitant to do work with this plant ignoring centuries of evidence there were some health benefits,” Butt said. “Today could be a notable turning point… We don’t think this is the last deal we will see in the sector.”
Get daily cannabis business news updates. Subscribe
Related Articles
Thanks for reading our latest news article. Stay up to date on the latest hemp news, sourced and approved by HempRevs. If you have any questions or comments, please feel free to leave us a message in the comments!
Sign up for our weekly newsletter to stay up to date on the latest Industry news and keep an eye out for our next news story!
Source Disclaimer: This article was was sourced from Ganjapreneur.com (the Original Publisher). In order to maintain the functionality, trust, and safety of HempRevs.com, the content sourced from the Original Publisher may have been altered. Read the original article here:
GW Pharmaceuticals Will Be Acquired for $7.2 Billion